Pharma BD Deal Intelligence
Novo pays up to $5.2B for Akero's efruxifermin, the largest of three FGF21 buyouts in five months and a direct hedge after Novo's own internal FGF21 program failed, though it still trails Roche and Genentech into the class.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →On October 9, 2025, Akero Therapeutics, Inc. entered into an Agreement and Plan of Merger with Novo Nordisk A/S and a wholly-owned subsidiary, pursuant to…
Novo Nordisk is spending up to $5.2 billion to acquire Akero Therapeutics and its Phase 3 FGF21 analogue efruxifermin, adding a potential best-in-class MASH…
Novo Nordisk to buy Akero Therapeutics, picking up promising MASH drug. The upfront payment values the company at $4.7 billion, with shareholders potentially…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Novo Nordisk agreed to acquire Akero for $54/share cash (~$4.7B) plus CVR of $6/share ($500M), total up to $5.2B. Gains efruxifermin, potentially best-in-class FGF21 analogue in Phase 3 for MASH (F2-F3 and F4/cirrhosis). Largest of three major FGF21 acquisitions in five months. Closed December 9, 2025.
17M US cases/yr · $15.0B Projected US MASH Market by 2030
Metabolic dysfunction-associated steatohepatitis (MASH), formerly non-alcoholic steatohepatitis (NASH), is a progressive liver disease characterized by hepatic steatosis, lobular inflammation, and hepatocyte ballooning, which can progress to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. It is the hepatic manifestation of metabolic syndrome and is tightly linked to obesity, type 2 diabetes, insulin resistance, and dyslipidemia. MASH represents the fastest-growing indication for liver transplantation in the United States. The disease is histologically staged by NAS score and fibrosis stage (F0-F4), with F2-F3 representing the at-risk population with significant fibrosis and F4 representing compensated cirrhosis. Diagnosis has historically required liver biopsy, though non-invasive tests including FibroScan, MRI-PDFF, and proprietary blood panels (ELF, FIB-4) are increasingly used for screening and monitoring. The first FDA-approved MASH-specific therapy, Madrigal's Rezdiffra (resmetirom), was approved in March 2024 for non-cirrhotic F2-F3 patients, establishing a regulatory pathway based on biopsy-confirmed histologic improvement. Obesity drugs including GLP-1 agonists have demonstrated MASH activity, further intensifying competitive dynamics.
The MASH competitive landscape is rapidly evolving. Rezdiffra (resmetirom, Madrigal Pharmaceuticals), a liver-directed thyroid hormone receptor-beta agonist, is the first and only FDA-approved MASH therapy (March 2024) for non-cirrhotic F2-F3. The FGF21 analogue class includes efruxifermin (Akero, acquired by Novo Nordisk), pegozafermin (89bio, being acquired by Roche), and BIO89-100; all showed fibrosis improvement signals in Phase 2b. GLP-1/GIP/glucagon multi-agonists with MASH activity include semaglutide (Novo Nordisk's Wegovy/Ozempic, ESSENCE Phase 3), tirzepatide (Eli Lilly's Mounjaro/Zepbound, SYNERGY-NASH), survodutide (Boehringer/Zealand, Phase 3), and retatrutide (Eli Lilly). FGF19 analogue aldafermin (NGM Biopharmaceuticals) was discontinued. PPAR agonists include lanifibranor (Inventiva, NATiV3 Phase 3). THR-beta agonist VK2809 (Viking Therapeutics) and FASN inhibitor denifanstat (Sagimet) represent earlier-stage approaches.
Acquisition closed Dec 9, 2025. Akero shareholders received $54/share cash (~$4.7B) plus a non-tradeable CVR of $6/share (~$0.5B) contingent on US regulatory approval of efruxifermin. Akero became a wholly owned subsidiary of Novo Nordisk and was delisted from Nasdaq.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / Akero Therapeutics, Inc. (this deal) | 2025 | $5.2B | — |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2025 deals · Novo Nordisk A/S deals · Infectious Disease deals